Arene’s focus is to reduce the time to market for the unique products in the portfolio to make dominating presence in the infectious disease areas. We are also widening the portfolio to other key infectious disease of Anti-TB and HCV.
Facilitating capacity building and collaboration between various regulators. Contributing to market sustainability and lower prices by increasing fair competition among quality products and reducing the cost with chemistry improvements to increase the efficiency and productivity.
We are actively seeking to partner with Global pharmaceutical formulation manufacturers to be their preferred quality API suppliers for both access and regulated markets, as we are completely backward integrated and would be contributing significantly to meet the growing demand.
| Therapeutic Category | APIs | Filing Status |
|---|---|---|
| Antihypertensive |
|
|
| Cough Suppressant | Levodropropizine | CEP + Global Filings |
| Anti Diabetic | Imeglimin Hydrochloride | DMF Available |
| CNS |
|
|
| Analgesics |
|
|
| Antiinflammation | Etoricoxib | U/Filing |
| Anticoagulant |
|
|
| Antifungal | Fluconazole | CEP + Global Filings |
| Antihistamine |
|
|
| Anti-TB/ Antibacterial |
|
|
| Antiviral |
|
|
| Antiretroviral |
|
|
| Antimigraine | Rimegepant | USDMF U/Filing |
| Spasmolytic Agent | Trimebutine Maleate | CEP U/filing |
| *Controlled Products in some jurisdiction. To be sold with a valid import permit only | ||